RESUMO
BACKGROUND: The cobas TaqScreen MPX Test, version 2.0, a multiplex, multi-dye nucleic acid amplification technology (NAT) test from Roche was evaluated by two European Blood Banks, the German Red Cross Blood Donor Service, Frankfurt, Germany and Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain. In addition, the cobas TaqScreen DPX Test was evaluated for the simultaneous detection and quantitation of parvovirus B19 and the detection of hepatitis A virus (HAV). STUDY DESIGN AND METHODS: The performances of the two tests were evaluated regarding the analytical sensitivity, the reproducibility of the tests using samples containing low concentrations of each virus and cross-contamination using samples containing high titres of virus. RESULTS: The analytical sensitivity of the MPX Test, version 2.0, obtained by the German Red Cross Blood Donor Service was 1·1, 3·9 and 43·3 IU/ml for HBV, HCV and HIV-1, respectively. The comparable analytical sensitivity at Centro de Hemoterapia y Hemodonación de Castilla y León was 3·5, 17·6 and 50·6 IU/ml for HBV, HCV and HIV-1, respectively. The analytical sensitivity of the DPX test determined by the German Red Cross Blood Donor Service was 0·6 and 3·8 IU/ml for HAV and B19. CONCLUSION: These multiplex and multi-dye blood screening assays represent a flexible NAT screening system for mini-pools between 6 and 96 samples per pool and fulfil all requirements of the European Pharmacopoeia for HCV and B19V testing of plasma for fractionation. The inclusion of a new multi-dye technology means discriminatory assays are no longer required for either test thus improving workflow, turn-around time and minimize the risk of obtaining a reactive result for which the virus cannot be identified.
Assuntos
Segurança do Sangue , Infecções por HIV/diagnóstico , Hepatite B/diagnóstico , Hepatite C/diagnóstico , Técnicas de Amplificação de Ácido Nucleico , Bancos de Sangue , Doadores de Sangue , Europa (Continente) , Genótipo , Infecções por HIV/virologia , HIV-1/genética , HIV-2/genética , Hepacivirus/genética , Hepatite A/diagnóstico , Hepatite A/virologia , Vírus da Hepatite A/genética , Hepatite B/virologia , Vírus da Hepatite B/genética , Hepatite C/virologia , Humanos , Programas de Rastreamento , Parvovirus B19 Humano/genética , Reprodutibilidade dos TestesRESUMO
BACKGROUND: The residual risk for bacterial contamination in blood components especially in platelets is one to two orders of magnitude higher than for transfusion relevant viral infections. The majority of all bacterial transmitted fatalities occurred at the end of platelet shelf life. Therefore, the maximum shelf life of platelet concentrates (PC) was reduced to 4 days after blood donation in Germany in 2008. METHODS: A new continuous non-invasive bacterial detection method was developed by O(2) measurements in the platelet fluids and tested with 10 transfusion relevant bacteria species. RESULTS: The bacterial concentration at the time point of a positive signal of PreSense O(2) ranged between 10(2) and 10(5) CFU mL(-1) . Harmful transfusion-transmitted bacterial infection would have probably been prevented by this novel technology. Only strict anaerobic bacteria strains like Clostridium perfringens were not detected within the study period of 72 h. CONCLUSIONS: The described non-invasive bacterial detection method represents a new approach to prevent transmission of bacterial infection in platelets. The method is characterised by the advantage that all investigations can be performed until right up to the time of transfusion, and therefore, reduce the risk for sample errors to a minimum.
Assuntos
Plaquetas/microbiologia , Preservação de Sangue , Soluções para Preservação de Órgãos/química , Oximetria/métodos , Oxigênio/análise , Aerobiose , Bacillus cereus/metabolismo , Infecções Bacterianas/prevenção & controle , Infecções Bacterianas/transmissão , Plaquetas/química , Clostridium perfringens/metabolismo , Processamento Eletrônico de Dados , Enterobacteriaceae/metabolismo , Humanos , Técnicas In Vitro , Medições Luminescentes , Oximetria/instrumentação , Projetos Piloto , Transfusão de Plaquetas/efeitos adversos , Staphylococcus/metabolismo , Fatores de TempoRESUMO
BACKGROUND: The Paul-Ehrlich-Institute analysed all fatalities due to bacterial infections between 1997 and 2007. Thereafter, the platelet shelf life was reduced to a maximum of 4 days after blood donation because the majority of all cases of severe transfusion-transmitted bacterial infections occurred with day 5 platelets. The current study compares the analytical sensitivity and the diagnostic specificity of four rapid bacterial detection procedures. METHODS: Nine transfusion-relevant bacterial strains were spiked in pooled platelets or apheresis platelets at a low concentration (10 CFU/bag). Samples were collected after day 3, day 4 and day 5 and investigated by four rapid bacterial detection methods (modified BacT/ALERT, Bactiflow, FACS method and 16s DNA PCR methods). RESULTS: Seven out of nine bacterial strains were adequately detected by BacT/ALERT, Bactiflow and PCR in apheresis platelets and pooled platelets after sample collection at day 3, day 4 and day 5. For three bacterial strains, analytical sensitivity was reduced for the FACS method. Two bacterial strains did not grow under the storage conditions in either pooled or apheresis platelets. CONCLUSIONS: A late sample collection on day 3, day 4 or day 5 after blood donation in combination with a rapid bacterial detection method offers a new opportunity to improve blood safety and reduce errors due to sampling., BacT/ALERT, Bactiflow or 16s ID-NAT are feasible for late bacterial screening in platelets may provide data which support the extension of platelet shelf life in Germany to 5 days.
Assuntos
Bactérias , Infecções Bacterianas/sangue , Transfusão de Componentes Sanguíneos , Doadores de Sangue , Plaquetas/microbiologia , Preservação de Sangue/métodos , Patógenos Transmitidos pelo Sangue , DNA Bacteriano/sangue , Infecções Bacterianas/genética , Infecções Bacterianas/microbiologia , Alemanha , Humanos , Reação em Cadeia da Polimerase/métodos , Fatores de TempoRESUMO
BACKGROUND: In 1997 the German Red Cross (GRC) blood donor services introduced mini-pool nucleic acid testing (NAT) for human immunodeficiency virus (HIV)-1, hepatitis C virus (HCV) and hepatitis B virus (HBV) to increase blood safety. With the new cobas s 201/cobas TaqScreen MPX, a fully automated extraction method and a multiplex amplification system specifically adapted to the needs of blood donation services is available. METHODS: The cobas s 201 system was evaluated at the GRC BTS locations Hagen, Springe and Frankfurt. In phase A, the analytical sensitivity for the detection of HBV, HCV and HIV-1 was investigated and in phase B, at least 60,000 samples at each test site were screened in parallel with the MPX test on s 201 system and the existing routine mini-pool NAT system to compare the diagnostic specificity and the diagnostic sensitivity. RESULTS: Comparable analytical sensitivities in a range of 1.6-3.6 IU/ml, 4.9-10.9 IU/ml and 14.7-26.6 IU/ml for HBV, HCV HIV, respectively, for the MPX test on s 201 system (95% probability based on probit analysis) were determined at all test sites. The diagnostic sensitivity was 99.8% and the diagnostic specificity was 99.85%. CONCLUSIONS: The MPX test on s 201 system is a fully automated NAT system suitable for routine blood donor screening. The analytical sensitivity as well as the diagnostic sensitivity fulfilled all requirements of the Paul Ehrlich Institute for blood donor screening in mini-pools up to 96 donations per pool. A major benefit of the automated NAT system is the reduced personnel time and the extensive complete barcode-controlled process documentation.
Assuntos
Doadores de Sangue , Programas de Rastreamento/instrumentação , Programas de Rastreamento/métodos , Viroses/diagnóstico , Automação , Processamento Eletrônico de Dados , Alemanha , HIV-1/isolamento & purificação , Hepacivirus/isolamento & purificação , Vírus da Hepatite B/isolamento & purificação , Humanos , Cruz Vermelha , Sensibilidade e Especificidade , Viroses/prevenção & controle , Viroses/transmissãoAssuntos
Transfusão de Sangue/estatística & dados numéricos , Transmissão de Doença Infecciosa/estatística & dados numéricos , Infecções por HIV/epidemiologia , Hepatite C/epidemiologia , Programas de Rastreamento/estatística & dados numéricos , Técnicas de Amplificação de Ácido Nucleico/estatística & dados numéricos , Medição de Risco/métodos , Doadores de Sangue , Transfusão de Sangue/métodos , DNA Viral/sangue , Infecções por HIV/transmissão , Hepatite C/transmissão , Humanos , Cooperação Internacional , Programas de Rastreamento/tendências , Fatores de Risco , Inquéritos e QuestionáriosRESUMO
Eastern Austria is neighbouring regions with ongoing West Nile virus (WNV) transmissions. Three human WNV infections had been diagnosed during the past decade in Austria. The Austrian Red Cross Blood Service (ARC-BS) started a first voluntary screening for WNV in blood donors from Eastern Austria by Nucleic Acid Testing (NAT) in June 2014. This is also the most extensive WNV surveillance programme in humans in Austria so far. In August 2014, one autochthonous WNV infection was detected in a blood donor from Vienna. By now, one in 67,800 whole blood donations was found to be positive for WNV RNA.
Assuntos
Doadores de Sangue , Febre do Nilo Ocidental/diagnóstico , Febre do Nilo Ocidental/virologia , Vírus do Nilo Ocidental/isolamento & purificação , Adulto , Áustria/epidemiologia , Feminino , Genoma Viral , Humanos , Programas de Rastreamento , Técnicas de Amplificação de Ácido Nucleico , Filogenia , RNA Viral/sangue , Febre do Nilo Ocidental/epidemiologiaRESUMO
Compared to HIV and hepatitis C virus, the residual infectious risk of hepatitis B virus (HBV) posed by blood products is about 10 times higher. In addition to HBsAg testing, screening for anti-HBc was recommended by the German Advisory Committee Blood in March 2005. Prevalence of anti-HBc in German blood donors was investigated at five test sites located in different geographic regions. In total, 12,000 blood donors were screened for anti-HBc by PRISM HBcore, and a statistically representative number of these were tested with Abbott Murex anti-HBc total, bioMérieux Hepanostika anti-HBc uniform, Bio-Rad Monolisa anti-HBc PLUS and Dade Behring Enzygnost anti-HBc. Anti-HBc repeat reactive samples were tested for anti-HBs, anti-HBe and HBV DNA by individual donation NAT. The mean prevalence of anti-HBc was 1.75% in donors that had not been tested for anti-HBc in the past. The percentage of anti-HBs in anti-HBc repeat reactive donors was 93.7%. Samples that were additionally reactive for anti-HBe were anti-HBc reactive in all tested assays. The sample to cut-off (S/Co) values for anti-HBc were lower (competitive assays) in samples that were also positive for anti-HBe, when compared to samples that were only anti-HBc reactive. Most commercially available anti-HBc assays provide sufficient sensitivity for routine screening purposes, and lacking specificity is no longer a serious issue for most of them. Assay differences were recognized for samples that were anti-HBc only reactive. The overall loss of 1.75% of positive testing donors can be significantly reduced to 0.45% by implementation of re-entry procedures for donors with an anti-HBs titre of over 100 IU/l and negative by sensitive ID-NAT.
Assuntos
Seleção do Doador , Antígenos do Núcleo do Vírus da Hepatite B/imunologia , Vírus da Hepatite B/imunologia , Doadores de Sangue , Controle de Doenças Transmissíveis , DNA Viral/sangue , Alemanha/epidemiologia , Hepatite B/sangue , Hepatite B/epidemiologia , Anticorpos Anti-Hepatite B/sangue , Antígenos do Núcleo do Vírus da Hepatite B/análise , Antígenos de Superfície da Hepatite B/sangue , Humanos , Sensibilidade e EspecificidadeRESUMO
BACKGROUND AND AIMS: When performing minipool testing of blood donations for transfusion-transmissible viruses, it is crucial to correctly dispense plasma from each donation into the pools. However, concerns regarding the monitoring and documentation of the pooling process exist. METHODS: A balance module with a tube holder has been developed, which can be easily integrated into liquid handling platforms. The existing software monitors and evaluates every single dispensing from primary samples to the minipool to confirm liquid arrival. The weighing accuracy of the balance module is approximately 2 mg per dispensing episode. RESULTS: Ten thousand one hundred and fifty-six blood donations were tested on a Tecan Genesis RSP pipetting system. Thirty-one donations were not pipetted because the pipetting workstation identified a clot or sample shortage in the primary tube. The balance module exclusively detected another 18 mispipettings, which were outside of the acceptance criteria of 100 +/- 10%. The mean pipetted volume for these samples was 34.2 microl (range 0-87 microl). Visual inspection of the corresponding primary tubes showed blood clots, short sample or no apparent cause. The average deceleration of the pooling process, using the balance, was determined to be about 22%. CONCLUSIONS: With the novel liquid arrival check system, complete and consistent process documentation of pooling for nucleic acid amplification technology (NAT) testing is feasible. It enables blood banks to monitor and compare every single dispense made with predefined, required volumes. Results can be transferred to the laboratory information management system for automated selective exclusion of inaccurately dispensed samples. ONE SENTENCE SUMMARY: Monitoring and documenting the pooling process for NAT testing using a balance-based liquid arrival check system.
Assuntos
Patógenos Transmitidos pelo Sangue , Seleção do Doador , Sistemas Computadorizados de Registros Médicos/instrumentação , Plasma/virologia , Reação em Cadeia da Polimerase/instrumentação , Viroses/prevenção & controle , Doadores de Sangue , Seleção do Doador/métodos , Humanos , Viroses/genéticaRESUMO
Culture methods for bacterial detection (BacT/ALERT or Pall eBDS) are currently implemented in blood donor screening procedures in many countries. Experience in the first years after implementation of these detection assays showed that although the analytical sensitivity was extremely high (about 1 CFU mL(-1)), the majority of these platelets were still transfused before a positive screening result was attained. Rapid technologies were developed to more effectively prevent transfusion-transmitted bacterial infection. In this study, a new rapid bacterial detection method based on fluorescence-activated cell sorting (FACS) technology was developed. Bacteria were stained with thiazole orange dye for 5 min and measurement was taken immediately after staining. The entire process took only 30 min. Six transfusion-relevant bacteria strains were tested in a spiking study. Without pre-incubation in a special bacteria growth medium, analytical sensitivity ranged between 10(5) CFU mL(-1) (Klebsiella oxytoca and Serratia marcesens) and 10(3) CFU mL(-1) (Escherichia coli). Sensitivity could be improved to 10(1) CFU mL(-1) for all tested bacteria by adding a pre-incubation step (6 h at 37 degrees C). Although preliminary in nature, results of our study suggest that bacterial detection by FACS technology in conjunction with a pre-incubation step offers a sensitive alternative technology to culture methods. Additionally, it provides the benefit of a rapid test time and the opportunity of preventing bacterial transmitted infections more effectively.
Assuntos
Técnicas Bacteriológicas/métodos , Plaquetas/microbiologia , Seleção do Doador/métodos , Citometria de Fluxo/métodos , Técnicas Bacteriológicas/instrumentação , Contagem de Colônia Microbiana/métodos , Humanos , Transfusão de Plaquetas/efeitos adversos , Sensibilidade e Especificidade , Fatores de TempoRESUMO
BACKGROUND AND OBJECTIVES: The optimized scansystem could detect contaminated platelet products within 24 h. However, the system's sensitivity was reduced by a high fluorescence background even in sterile samples, which led to the necessity of a well-trained staff for confirmation of microscope results. MATERIALS AND METHODS: A new protocol of the optimized scansystem with the addition of a fluorescence quencher was evaluated. Pool platelet concentrates contaminated with five transfusion-relevant bacterial strains were tested in a blind study. RESULTS: In conjunction with new analysis software, the new quenching dye was able to reduce significantly unspecific background fluorescence. Sensitivity was best for Bacillus cereus and Escherichia coli (3 CFU/ml). DISCUSSION: The application of a fluorescence quencher enables automated discrimination of positive and negative test results in 60% of all analysed samples.
Assuntos
Técnicas Bacteriológicas/métodos , Plaquetas/microbiologia , Técnicas Bacteriológicas/estatística & dados numéricos , Contagem de Colônia Microbiana , Corantes Fluorescentes , Humanos , Sensibilidade e Especificidade , Sepse/prevenção & controle , Reação TransfusionalRESUMO
BACKGROUND AND OBJECTIVES: Since voluntary introduction of hepatitis B virus (HBV) minipool nucleic acid amplification technology (NAT) at the German Red Cross, the expected residual risk of a transfusion-associated HBV infection has been estimated to be 1 : 500,000 - about 10 times higher than for human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection. Donors demonstrating chronic positivity for antibody to hepatitis B core antigen (anti-HBc), negativity for hepatitis B surface antigen (HBsAg) and polymerase chain reaction (PCR)-negative with a low virus load are a major cause of this increased risk. MATERIALS AND METHODS: Ten-thousand blood donors from our blood-donation centre were screened for anti-HBc using the current PRISM HBc and the new PRISM HBcore assay to evaluate the diagnostic sensitivity and specificity of these tests. PRISM HBc- or PRISM HBcore-reactive samples were further analysed using seven additional tests for anti-HBc, two tests for antibody to hepatitis B surface antigen (anti-HBs), one test for antibody to hepatitis B envelope antigen (anti-HBe) and three HBV NAT assays. RESULTS: From a total of 10,000 donors, nine and 14 samples were reactive only in the PRISM HBc and the PRISM HBcore, respectively, whereas 165 samples were reactive in both anti-HBc assays. Further analysis of these 188 anti-HBc-reactive specimens in a total of nine different anti-HBc assays revealed concordant results for 162 (86.2%) specimens. Sample cut-off values for anti-HBc were significantly (P < 0.01) lower for anti-HBc-only reactive samples compared with specimens that were also reactive for anti-HBs or anti-HBe. CONCLUSIONS: Both PRISM anti-HBc assays revealed that approximately 1.8% of non-prescreened blood donors from Germany were reactive for anti-HBc. Although sensitivity was comparable between both assays, specificity was increased significantly with the PRISM HBcore. High anti-HBc sample cut-off values were indicative for reactivity in other HBV parameters and for concordant results in the nine different anti-HBc assays. Look-back investigations are necessary to estimate the infection risk both of anti-HBc-only positive and of anti-HBc/anti-HBs-positive blood transfusions.
Assuntos
Doadores de Sangue , Antígenos do Núcleo do Vírus da Hepatite B/imunologia , Programas de Rastreamento/métodos , Alemanha , Hepatite B/prevenção & controle , Antígenos do Núcleo do Vírus da Hepatite B/genética , Antígenos de Superfície da Hepatite B/sangue , Antígenos de Superfície da Hepatite B/isolamento & purificação , Humanos , Técnicas de Amplificação de Ácido Nucleico/métodos , Sensibilidade e Especificidade , Carga ViralRESUMO
BACKGROUND AND OBJECTIVES: Nucleic acid extraction still harbours the potential for improvements in automation and sensitivity of nucleic acid amplification technology (NAT) testing. This study evaluates the feasibility of a novel automated high-volume extraction protocol for NAT minipool testing in a blood bank setting. MATERIALS AND METHODS: The chemagic Viral DNA/RNA Kit special for automated purification of viral nucleic acids from 9.6 ml of plasma by using the chemagic Magnetic Separation Module I was investigated. Analytical sensitivity for hepatitis C virus (HCV), human immunodeficiency virus-1 (HIV-1), hepatitis B virus (HBV), hepatitis A virus (HAV) and parvovirus B19 (B19) was compared to our present manual procedure that involves virus enrichment by centrifugation. RESULTS: Chemagic technology allows automation of the viral DNA/RNA extraction process. Viral nucleic acids were bound directly to magnetic beads from 9.6-ml minipools. By combining the automated magnetic beads-based extraction technology with our in-house TaqMan polymerase chain reaction (PCR) assays, 95% detection limits were 280 IU/ml for HCV, 4955 IU/ml for HIV-1, 249 IU/ml for HBV, 462 IU/ml for HAV and 460 IU/ml for B19, calculated for an individual donation in a pool of 96 donors. The detection limits of our present method were 460 IU/ml for HCV, 879 IU/ml for HIV-1, 90 IU/ml for HBV, 203 IU/ml for HAV and 314 IU/ml for B19. CONCLUSIONS: The 95% detection limits obtained by using the chemagic method were within the regulatory requirements for blood donor screening. The sensitivities detected for HCV, HBV, HAV and B19 were found to be in a range similar to that of the manual purification method. Sensitivity for HIV-1, however, was found to be inferior for the chemagic method in this study.